Dendreon Announces Webcast Presentations at Upcoming Investor Conferences Sep 5, 2009
SEATTLE, Sept. 4 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: ) today announced that management will present at the following four upcoming investor conferences ... Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics ... SOURCE Dendreon Corporation. (PR Newswire)
Dont give ObamaCare supporters ammunition Aug 19, 2009
Ms. Bayh is a director of Dendreon Corporation (biotechnology), Curis, Inc. (biomedical), Emmis Communications Corporation (media), and Dyax Corporation (biopharmaceutical company) ... Ms. Bayh is a director of Dendreon Corporation (biotechnology), Curis, Inc. (biomedical), Emmis Communications Corporation (media), and Dyax Corporation (biopharmaceutical company). (Atlanta Journal-Constitution -- Opinion)
Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer Apr 20, 2009
SEATTLE and DENVER, April 19 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: ) presented today data from its PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 study suggesting that PROVENGE(R) (sipuleucel-T) induces long-term memory immune responses that are durable and can be maintained following boosting ... Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and... (PR Newswire)
Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial Apr 14, 2009
SEATTLE, April 13 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: ) will host a conference call tomorrow, Tuesday, April 14, 2009, at 9:00 AM ET (6:00 AM PT) to review the outcome of the FINAL analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer ... Dendreon Corporation is a biotechnology... (PR Newswire)
LiquidTycoon.com Issues Technical Trade Alerts On Hot Stocks With Monster Potential: GOOG, CREE, DNDN, COMS, WZEN, & DTO Apr 8, 2009
Today's focused alerts include: Google Inc. (Nasdaq: ), Cree Inc. (Nasdaq: ), Dendreon Corporation (Nasdaq: ), 3COM Corporation (Nasdaq: ), Webzen Inc. (Nasdaq: ) and Powershares DB Crude (NYSE: ). alerts its members daily on stocks that are hot in the market. (PR Newswire)
